|
|
|
|
Discover how you can save up to 40% in your drug development timeline by partnering with an integrated CRO/CDMO that can safely advance your product seamlessly through each development phase with accelerated timelines and cost savings, ease of data transfer, and fewer logistical challenges.
|
|
|
|
|
Are you looking for a partner that can support your ophthalmic drug development program from lead candidate selection to clinical proof-of-concept, and beyond? Learn how Altasciences' end-to-end services can optimize your program and get your products to market faster.
|
|
|
|
|
Scientific experts share essential approaches and techniques for administering gene therapies accurately to an intended anatomical target area in an organ of interest, such as the brain or eye, illustrated with several examples.
|
|
|
|
|
Globally recognized consultants discuss key considerations in developing ophthalmic drugs such as bioavailability, patient safety, preclinical and clinical study design, and the latest advancements in the field.
|
|
|
|
|
Industry-leader in ophthalmic safety assessments with 30+ years of experience, having set the foundation for the commercial success of numerous ocular therapeutics on the market today.
|
|
|
|
|
|
Your Top Partner For Ophthalmic Drug Development
|
Altasciences, a leading partner in ocular therapy, can support your ophthalmic drug development program from prototype formulation through preclinical testing to early-phase clinical trials, to manufacturing and commercialization ― providing up to 40% in time savings.
|
|
• Request Information
|
|
|
|
|
|
|
|
